EMERGENT BIOSOLUTIONS INC. Material Contracts
Every material contract the company filed as Exhibit 10 (executive pay plans, credit agreements, supplier and indemnity agreements), newest first, with the filing's own description.
- 2022-08-02: Form 10-Q; Exhibit 10.2; Description Modification No. 29, effective June 16, 2022, to the CDC BioThrax Procurement Contract.
- 2022-08-02: Form 10-Q; Exhibit 10.1; Description Modification No. 28, effective April 14, 2022, to the CDC BioThrax Procurement Contract.
- 2022-04-29: Form 10-Q; Exhibit 10.3; Description Consulting Agreement, dated as of March 18, 2022 and effective as of April 1, 2022, by and between Emergent BioSolutions Inc. and Fuad El-Hibri..
- 2022-04-29: Form 10-Q; Exhibit 10.1; Description Modification No. 27, effective March 31, 2022, to the Solicitation/Contract/Order for Commercial Items (the CDC BioThrax Procurement Contract), effective December 8, 2016, from the Centers for Disease Control and Prevention to Emergent Biodefense Operations Lansing LLC..
| Filed | Form | Exhibit | Description |
|---|
| 2022-08-02 | 10-Q | 10.2 | Modification No. 29, effective June 16, 2022, to the CDC BioThrax Procurement Contract |
|---|
| 2022-08-02 | 10-Q | 10.1 | Modification No. 28, effective April 14, 2022, to the CDC BioThrax Procurement Contract |
|---|
| 2022-04-29 | 10-Q | 10.3 | Consulting Agreement, dated as of March 18, 2022 and effective as of April 1, 2022, by and between Emergent BioSolutions Inc. and Fuad El-Hibri. |
|---|
| 2022-04-29 | 10-Q | 10.1 | Modification No. 27, effective March 31, 2022, to the Solicitation/Contract/Order for Commercial Items (the CDC BioThrax Procurement Contract), effective December 8, 2016, from the Centers for Disease Control and Prevention to Emergent Biodefense Operations Lansing LLC. |
|---|
| 2022-02-25 | 10-K | 10.101 | Modification No. 32, effective November 1, 2021, to the BARDA ADM Contract. |
|---|
| 2022-02-25 | 10-K | 10.100 | Modification No. 30, effective September 30, 2021, to the BARDA ADM Contract (incorporated by reference to Exhibit 10.7 to the Company's Quarterly Report on Form 10-Q filed on November 5, 2021). |
|---|
| 2022-02-25 | 10-K | 10.85 | Modification No. 8, effective November 1, 2021, to Task Order 75A50120F33007. |
|---|
| 2022-02-25 | 10-K | 10.76 | Modification No. 11, effective September 30, 2021, to the BARDA AV7909 Contract (incorporated by reference to Exhibit 10.4 to the Company's Quarterly Report on Form 10-Q filed on November 5, 2021). |
|---|
| 2022-02-25 | 10-K | 10.75 | Modification No. 3, effective October 1, 2021, to Task Order 75A50120F33006. |
|---|
| 2022-02-25 | 10-K | 10.71 | Modification No. 3, effective, April 1, 2021 to the ACAM2000 Contract (incorporated by reference to Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q filed on July 30, 2021). |
|---|
| 2022-02-25 | 10-K | 10.70 | Modification No. 5, effective, September 29, 2021 to the ACAM2000 Contract. |
|---|
| 2022-02-25 | 10-K | 10.69 | Modification No. 4, effective, July 13, 2021 to the ACAM2000 Contract. |
|---|
| 2022-02-25 | 10-K | 10.61 | Modification No. 12, effective December 2, 2021, to the BARDA AV7909 Contract. |
|---|
| 2022-02-25 | 10-K | 10.48 | Modification No. 24, effective February 2, 2021, to the CDC BioThrax Procurement Contract. (incorporated by reference to Exhibit 10.5 to the Company's Quarterly Report on Form 10-Q filed on November 5, 2021). |
|---|
| 2022-02-22 | 8-K | 10 | Form of 2022-2024 Performance-Based Stock Unit Award Agreement. |
|---|